Preparing for SpaceX, Warsh's Rate Cut Outlook and More on Tuesday

Tuesday could be a volatility catalyst, led by Kevin Warsh’s Fed confirmation hearing at 10 a.m. ET and market expectations around any hints of rate cuts in 2026. A broad Q1 2026 earnings slate includes 3M, D.R. Horton, Danaher, GE Aerospace, Northrop Grumman, Quest Diagnostics, Tractor Supply and UnitedHealth, with guidance likely to shape S&P 500 EPS expectations. SpaceX’s analyst day could also influence IPO sentiment and benefit Morgan Stanley, Bank of America, and related private-market holdings.

Analysis

The immediate setup is a classic dispersion trade: anything tied to capital formation and advisory fees can outperform if SpaceX’s event improves the odds of a clean IPO path, but the larger second-order effect is on private-market markups. A credible read-through to monetization windows helps not just MS/BAC, but also portfolio companies sitting in late-stage venture inventories; that can support NAV optics for SSSS even before any actual listing, while GSAT becomes a pure sentiment lever if the market starts pricing a more valuable strategic ecosystem around SpaceX-linked demand.

The more important macro risk is that the market is currently paying up for the possibility of easier policy while refusing to fully price a no-cut baseline. If Warsh merely sounds orthodox, the relief trade may fade quickly; if he opens the door to cuts later this year, duration-sensitive equities should react first, but the move is vulnerable if incoming inflation or jobs data re-tighten expectations within days. In other words, the upside from a dovish hearing is front-loaded, while the downside from a hawkish one can persist for weeks through higher real yields and multiple compression.

Earnings are the cleaner catalyst for stock selection because guidance, not beats, is likely to drive cross-sector relative performance. The vulnerable cohort is companies with elevated expectations and low tolerance for even modest 2026 margin caution; that favors a short-duration approach to names where operating leverage is already fully priced and where soft commentary could drag the whole industrial/healthcare complex lower for 1-3 sessions. NFLX remains the cleanest example of the market’s intolerance for softer outlooks, so the read-through is that surprise compression matters more than absolute print quality.

Key Decisions for Investors

• Add MS/BAC on any morning dip tied to the SpaceX event; use a 1-3 day horizon and size for a quick fee-led sentiment pop rather than a fundamental rerate.
• Consider a tactical long SSSS vs short a basket of public growth/VC proxies for 1-2 weeks if SpaceX commentary is supportive; the trade is on improved private-markets mark-to-market and IPO monetization optionality.
• If Warsh sounds even modestly dovish, buy short-duration rate-sensitive equities for a 24-48 hour trade; if he is strictly orthodox, fade the initial bounce and expect higher real-rate pressure to reassert.
• Use earnings to short names with crowded guidance expectations via put spreads into prints, especially where consensus has little margin for caution; the payoff is better on the downside than chasing upside beats.
• Stay long AMZN as an indirect beneficiary of venture/IP0 ecosystem health, but treat GSAT as a higher-beta event trade only if SpaceX messaging suggests a broader strategic uplift.